Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IOSP
IOSP logo

IOSP Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Innospec Inc (IOSP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
82.730
1 Day change
-0.46%
52 Week Range
92.140
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Innospec Inc (IOSP) does not present a compelling buy opportunity for a beginner investor with a long-term focus at this time. The technical indicators are mixed, with no strong bullish momentum, and the options data suggests a neutral to slightly bearish sentiment. Additionally, there are no significant positive catalysts or recent financial data to support a strong buy recommendation.

Technical Analysis

The MACD histogram is negative and expanding downward, indicating bearish momentum. RSI is neutral at 44.119, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot level of 83.809, with key support at 80.849 and resistance at 86.77.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The open interest put-call ratio of 1.5 suggests a bearish sentiment, while the option volume put-call ratio of 0.0 indicates minimal trading activity in options.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
8

Positive Catalysts

  • NULL identified. There is no recent news, no significant hedge fund or insider trading activity, and no recent congress trading data.

Neutral/Negative Catalysts

  • The stock has a 70% chance of declining by -0.53% in the next day, -0.68% in the next week, and -2.27% in the next month. The MACD is bearish, and the options data leans towards a bearish sentiment.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available.

Wall Street analysts forecast IOSP stock price to rise
1 Analyst Rating
Wall Street analysts forecast IOSP stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 83.110
sliders
Low
93
Averages
93
High
93
Current: 83.110
sliders
Low
93
Averages
93
High
93
Freedom Capital
initiated
$93
AI Analysis
2025-11-17
Reason
Freedom Capital
Price Target
$93
AI Analysis
2025-11-17
initiated
Reason
Freedom Capital initiated coverage of Innospec with a Buy rating and $93 price target, calling the company an "undervalued" specialty chemicals maker. The firm said it sees potential upside from either new product offerings or opportunistic M&A. Freedom Capital noted that the stock's recent underperformance along with its bottoming earnings "create an attractive risk-reward tradeoff."

People Also Watch